Innovative Paradigms for ART: Implementation Insights From an Expert Panel

Download slide highlights from our live symposium.

Chloe Orkin, MBChB, FRCP, MD
Program Director Andrea Mantsios, PhD Anthony M. Mills, MD Omar Sued, MD, PhD Babafemi Taiwo, MBBS Released: July 19, 2019

Learn from expert faculty as they respond to the most pressing questions on evolving paradigms in ART, including two-drug regimens and long-acting injectable therapy.

Chloe Orkin, MBChB, FRCP, MD
Program Director Andrea Mantsios, PhD Anthony M. Mills, MD Omar Sued, MD, PhD Babafemi Taiwo, MBBS Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Released: September 24, 2019 Expired: No longer available for credit

Download slide highlights of expert faculty responses to the most pressing clinician questions on novel ART.

Chloe Orkin, MBChB, FRCP, MD
Program Director Andrea Mantsios, PhD Anthony M. Mills, MD Omar Sued, MD, PhD Babafemi Taiwo, MBBS Released: September 24, 2019

Watch this on-demand Webcast of a CCO symposium at IAS 2019 to gain expert perspectives on evolving paradigms in ART, including two-drug regimens and long-acting injectable therapy. Learn from an international faculty panel as they engage in detailed discussions about novel ART approaches.

Chloe Orkin, MBChB, FRCP, MD
Program Director Andrea Mantsios, PhD Anthony M. Mills, MD Omar Sued, MD, PhD Babafemi Taiwo, MBBS Physicians: maximum of 1.5 AMA PRA Category 1 Credits™ Released: August 26, 2019 Expired: No longer available for credit

Part 1: New Paradigms for ART (16 mins)

Part 2: How Confident Are We With the Efficacy and Safety of Oral Two-Drug Regimens? (12 mins)

Part 3: Should I Consider Two-Drug Regimens for Most Patients in My Practice or for Just a Select Few? (6 mins)

Part 4: Is Baseline Resistance Testing Important for Two-Drug Regimens? (16 mins)

Part 5: LA ART: Will the Positive Clinical Trial Results Translate to Long-term Efficacy/Safety and Real-World Experience? (12 mins)

Part 6: What Have Patients’ Experiences Been on LA Therapy? (16 mins)

Part 7: What Are the Challenges of LA Injectable ART for the Provision of HIV Care? (13 mins)

Current HIV guidelines limit their recommendations for dual ART, but I expect positive data will soon change this.

Omar Sued, MD, PhD Released: September 20, 2019

The question of which patients are candidates for long-acting ART might be a question of which patients want it.

Andrea Mantsios, PhD Released: September 27, 2019

Less frequent dosing may be a welcome theme among HIV drugs under investigation.

Babafemi Taiwo, MBBS Released: October 10, 2019

Why I believe as many as 70% of my patients will be interested in long-acting injectable ART.

Anthony M. Mills, MD Released: December 11, 2019